Caladrius gets late-stage cell therapy from Shire

Shire plc (LSE:SHP; NASDAQ:SHPG) granted Caladrius Biosciences Inc. (NASDAQ:CLBS) an exclusive, worldwide license to data and regulatory filings for a late-stage CD34+ cell therapy program to treat refractory angina. Shire will receive an upfront payment and be eligible for milestones and royalties, but declined to disclose specific financial terms.

Shire also declined to disclose the name of the program, but said the data set it out-licensed includes information from Phase I, II and III trials...